Advertisement

European Journal of Dermatology

, Volume 28, Issue 5, pp 702–704 | Cite as

Psoriasis induced by trastuzumab therapy

  • Caroline De LorenziEmail author
  • Gürkan Kaya
  • Sandrine Quenan
Article
  • 2 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kim DH, Jeong NJ, Lee Y, et al. Psoriasis induced by trastuzumab (herceptin®). Ann Dermatol 2013; 25: 229–31.CrossRefGoogle Scholar
  2. 2.
    Bianchini G, Kiermaier A, Biochi GV, et al. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2–positive breast cancer. Breast Cancer Res 2017; 19: 16.CrossRefGoogle Scholar
  3. 3.
    Aitelhaj M, Lkhoyaali S, Rais G, et al. First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive–Observational institutional study. Pan Afr Med J 2016; 24: 324.CrossRefGoogle Scholar
  4. 4.
    Di Modica M, Taglaiblue E, Triulzi T. Predicting the efficacy of HER2–targeted therapies: a look at the host. Dis Markers 2017; 2017: 7849108.CrossRefGoogle Scholar
  5. 5.
    Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Target Oncol 2010; 5: 295–6.CrossRefGoogle Scholar
  6. 6.
    De Potter Y, Poumay Y, Squillace KA, et al. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 2001; 271: 315–28.CrossRefGoogle Scholar
  7. 7.
    Garnock–Jones KP, Keating GM, Scott LJ. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)–positive early breast cancer. Drugs 2010; 70: 215–39.CrossRefGoogle Scholar
  8. 8.
    Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109–19.CrossRefGoogle Scholar
  9. 9.
    Macdonald JS. Toxicity of 5–fluorouracil. Oncology 1999; 13: 33–4.Google Scholar
  10. 10.
    Tan QW, Luo T, Zheng H, et al. Weekly taxane–anthracycline combination regimen versus tri–weekly anthracycline–based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial. Chin J Cancer 2017; 36: 27.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Caroline De Lorenzi
    • 1
    Email author
  • Gürkan Kaya
    • 1
  • Sandrine Quenan
    • 1
  1. 1.Dermatology and Venereology DepartmentUniversity Hospital of GenevaGenevaSwitzerland

Personalised recommendations